GSK (LON:GSK) Insider Sells £100,578.39 in Stock

GSK plc (LON:GSK) insider Luke Miels sold 4,549 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of GBX 2,211, for a total transaction of £100,578.39.

GSK Stock Up 1.1%

Shares of LON GSK opened at GBX 2,165 on Friday. The stock has a market capitalization of £87.35 billion, a price-to-earnings ratio of 16.28, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK plc has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 2,219. The firm has a 50-day moving average price of GBX 1,880.92 and a 200 day moving average price of GBX 1,693.82. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last issued its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities research analysts anticipate that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GSK has been the subject of several research reports. Shore Capital Group reaffirmed a “buy” rating and set a GBX 2,300 price objective on shares of GSK in a report on Wednesday, February 4th. Berenberg Bank raised their price target on GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research report on Monday, November 24th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research note on Thursday, January 15th. Finally, Jefferies Financial Group restated a “buy” rating and set a GBX 2,100 target price on shares of GSK in a research report on Wednesday, January 7th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of GBX 1,917.86.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.